Diffuse Large B-Cell Lymphoma Activated B-Cell Type — Variants & evidence

Diffuse Large B-Cell Lymphoma Activated B-Cell Type — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIM1 L2V1
Ibrutinib	Predictive	D	Supports Resistance	3	accepted	EID9945 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic
PIM1 P81S1
Ibrutinib	Predictive	D	Supports Resistance	3	accepted	EID9946 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic
PIM1 S97N1
Ibrutinib	Predictive	D	Supports Resistance	3	accepted	EID9947 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic

Data updated 4 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.